The data shared by Lundbeck is essential to CPAD’s work in creating a disease progression model across the entire continuum of AD
Lundbeck will share a unique set of clinical trial data from over 2,500 AD patients to the Critical Path for Alzheimer’s Disease (CPAD) consortium’s integrated database for qualified researchers to access. (Credit: Gerd Altmann/Pixabay.)
The Critical Path Institute (C-Path) and H. Lundbeck A/S (Lundbeck) have announced a data-sharing collaboration to provide advanced drug development tools in Alzheimer’s disease (AD).
Established in 2005, C-Path is an independent, nonprofit organisation created to improve the drug development process.
Under the data contribution agreement (DCA), Denmark-based pharmaceutical firm Lundbeck will share a unique set of clinical trial data from over 2,500 AD patients to the Critical Path for Alzheimer’s Disease (CPAD) consortium’s integrated database for qualified researchers across the world to access.
The agreement supported by Gates Ventures, will enable the integration of these clinical data and managed by CPAD, with assistance from C-Path’s Data Collaboration Center (DCC) adding to the CPAD patient-level database in AD.
Currently, CPAD patient-level database comprises data from over 14,500 patients.
CPAD is planning to accumulate current datasets from other sources with an expected growth of the CPAD database to contain more than 40,000 patient-level records in the upcoming months.
Lundbeck’s sharing of patient-level data consolidates the company’s continued support to intensify pre-competitive partnerships between pharmaceutical firms and academia, and to develop effective public-private partnerships.
Lundbeck experimental medicine and clinical development senior vice president Mads Dalsgaard: “We are delighted with this opportunity to share data with CPAD, ensuring that researchers can get the most out of them in advancing the understanding of Alzheimer’s and how to best develop new treatments.
“We are proud to contribute to this work, not only through our own drug development activities, but also in this unique collaboration.”
These contributions ensure that CPAD can continue its mission to advance innovative quantitative tools and methods to de-risk and accelerate the drug development tools in AD.
The data collected from Lundbeck’s Phase II and III studies evaluated the compound idalopirdine in AD
The data gathered from Lundbeck’s Phase II and III studies assessed the compound idalopirdine in AD and contain pertinent information about disease progression, drug effects and clinical trial design.
According to C-Path, the data shared by Lundbeck is essential to CPAD’s work in creating a disease progression model across the entire continuum of AD, from the earliest to late stages of the disease.
The main objective of CPAD is to provide advanced drug development tools that will help in enhancing clinical trial designs and execution and simplifying the regulatory review process.
C-Path president and CEO Joseph Scheeren said: “Lundbeck and C-Path recognise the hard work to generate these data and contributions of the many patients with Alzheimer disease, their relatives and caregivers, and the investigators who took part in these trials.
“We look forward to continuing to work together to advance and expedite the development of new therapies.”